wth will primarily be driven by an increase in the average number of days spent in the hospitals due to inappropriate initial and steady increase in elderly and immuno-suppressed population. At present the market has six approved therapies, out of which Vancomycin and Synercid (Quinupristin+Dalfopristin) are generic and rest four are branded drugs. Currently, the market is dominated by drugs like Vancomycin, Zyvox (linezolid) and Cubicin (daptomycin). As the disease is curable when identified in time, the unmet need seems to be low. Although the existing drugs such as Vancomycin, Zyvox, Cubicin, Tygacil (tygecycline), Vibativ (televancin) and Synercid are capable of curing the disease, still there are unmet needs which can be tapped with the emerging agents which have better safety.
ScopeThe report provides information on the key drivers and challenges of the MRSA market. Its Scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) MRSA market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as Penicillin-binding proteins (PBPs) binders, Transglycosylation and Transpeptidation inhibitor, Pleuromutilin bacterial protein synthesis inhibitor, CYP3A4-specific inhibitors and Membrane lysing action.
- Analysis of the current and future competition in the seven key countries MRSA market. Key market players covered are Takeda Pharmaceutical Company Limited/ Forest Laboratories, Merck & Co., Inc., Astrazeneca PLC, Trius Therapeutics, e-Therapeutics, Nabriva Therapeutics, TrioBiotics Pharma and Basilea Pharma.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis oPage: 1 2 3 4 Related medicine technology :1
. Reportlinker Adds US Disposable Medical Supplies Market Report2
. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile3
. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech4
. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery5
. Reportlinker Adds Reinventing Pharmaceutical Sales Forces6
. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 20147
. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery8
. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 20159
. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities10
. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis11
. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)